JPMorgan sets INR 1,600 target for Cipla stock

Published on 10/08/2026 at 11:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q1 FY27 revenue rose 2.33 percent to INR 71.19 billion. Cipla stock faces October 27 results after net income fell 39.18 percent year over year.

Cipla, INE059A01026, Illustration mit AI erstellt.

Cipla Limited (ISIN INE059A01026) had an Overweight rating and an INR 1,600 target from JPMorgan on October 7, 2026, according to The Financial Express. The target implied 19.50 percent upside in the source's comparison with the latest available trading level.

JPMorgan sees domestic and US support

JPMorgan's view rests on Cipla's India business and its respiratory portfolio in the United States. The brokerage expected India revenue to grow 12.00 percent year over year in the September quarter, while US respiratory and new products were expected to support a 7.00 percent increase in the US business, The Financial Express reported.

The product watchlist included gVentolin and gAdvaair, as well as Symbicort and peptide approvals or launches. For investors, the key comparison is between identifiable product catalysts and the weaker profit trend reported for the latest completed quarter.

Revenue grew as profit declined

In the first quarter of fiscal 2027, Cipla reported revenue from operations of INR 71.19 billion, up 2.33 percent from INR 69.57 billion a year earlier. Consolidated net income stood at INR 7.86 billion, down 39.18 percent from INR 12.92 billion in the year-ago quarter, while earnings per share fell to INR 9.77 from INR 16.07, according to DSIJ.

The figures leave revenue growth and earnings pressure moving in opposite directions. That divergence makes the September-quarter update particularly important because JPMorgan's positive view depends on operating improvement in both the domestic franchise and respiratory products.

NSE quote precedes October results

Cipla closed at INR 1,327.20 on the NSE on October 7, 2026. The NSE also showed a 52-week range of INR 1,165.70 to INR 1,673.00, market capitalization of INR 1,072.2 billion, and Nifty 50 membership on the same dated quote page.

The next results are scheduled for October 27, 2026, according to NSE India. That date will test whether revenue momentum can translate into improved profitability after the 39.18 percent year-over-year net income decline in the first quarter.